StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
No sell-side coverage available for ANIK.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Fundamentals not available for ANIK.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $14.80 | $14.54 | -1.76% | 0.1M |
| 05-12 | $14.45 | $14.68 | +1.59% | 0.1M |
| 05-13 | $14.54 | $14.80 | +1.79% | 0.0M |
| 05-14 | $14.84 | $15.34 | +3.37% | 0.1M |
| 05-15 | $15.16 | $14.83 | -2.18% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $29.61M | $112.82M | $82.20M | $54.39M |
Operating Income | $-5.49M | $-11.05M | $-11.70M | $-8.46M |
Net Income | $-5.06M | $-10.88M | $-11.17M | $-3.97M |
EPS (Diluted) | $-0.37 | $-0.76 | $-0.78 | $-0.62 |
Total Assets | $179.39M | $190.27M | $189.44M | $187.68M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $41.02M | $57.48M | $57.99M | $53.17M |
Free Cash Flow OCF − CapEx | $-6.28M | $4.36M | $373.00K | $-4.61M |
Shares Outstanding | 13.36M | 13.89M | 14.42M | 14.42M |